Skip to main content
Clinical Trials/NCT02250625
NCT02250625
Completed
Not Applicable

A Prospective Collection of Peripheral Blood Specimens to Study Vitamin D in Healthy Individuals

Fujirebio Diagnostics, Inc.1 site in 1 country482 target enrollmentMay 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vitamin D Deficiency
Sponsor
Fujirebio Diagnostics, Inc.
Enrollment
482
Locations
1
Primary Endpoint
Measure Vitamin D in healthy individuals
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

To obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting specimens from healthy subjects t on vitamin D assays, and to establish a collection of specimens that will support future assay discovery and validation efforts.

Detailed Description

1. Obtain matched serum and plasma specimens collected from a minimum of 50 healthy subjects in two geographic areas. Specimens will be used to determine a reference range for a vitamin D assay, used as an aid in the assessment of vitamin D sufficiency in adults. 2. Obtain serum specimens collected from a minimum of an additional 450 healthy subjects in two geographic areas. Specimens will be used to determine a reference range for a vitamin D assay, used as an aid in the assessment of vitamin D sufficiency in adults. 3. To store any remaining specimens for use in future vitamin D assay development and to evaluate as yet undetermined assays for the development of IVDs, including additional vitamin D assays

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
April 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males and females, age≥ 18 years Able to understand and willing to provide informed consent

Exclusion Criteria

  • Males and females, age \<18 years Current use of dietary supplements (tablet, liquid gel or liquid form only) containing high concentrations, greater than 2,000 IU per day, of vitamin D.
  • Has a history of vitamin D deficiency Has a history or current diagnosis of any clinically significant cardiac, respiratory, neurological, immunological, hematological, liver disease, renal disease, gastrointestinal (GI) disorder, including any history of peptic or gastric ulcers or GI bleeding, or any other condition which, in the opinion of the investigator is considered chronic.
  • Personal history of seizures Personal history of bariatric surgery Personal history of parathyroid and thyroid disease Pregnancy or lactation Is receiving systemic chemotherapy or radiation treatment, has an active malignancy of any type, or has been diagnosed with cancer within 5 years before screening other than basal or squamous cell skin cancers or in-situ cervical cancer.
  • Family history of parathyroid or calcium regulatory disease Medications known to affect absorption e.g. drugs that inhibit cholesterol absorption Medications known to increase catabolism such as anticonvulsants, glucocorticoids, HAART (AIDS treatment) and anti-rejection medications Unable to provide informed consent

Outcomes

Primary Outcomes

Measure Vitamin D in healthy individuals

Time Frame: 1 year

Study Sites (1)

Loading locations...

Similar Trials